Hyperinsulinism is a serious condition where the pancreas produces excessive amounts of insulin, leading to dangerously low blood sugar levels. This rare disorder requires immediate medical attention, particularly in newborns and infants, as prolonged episodes of low blood glucose can result in lasting neurological damage. Understanding treatment approaches—from established medications to emerging therapies being studied in clinical trials—is essential for managing this complex condition and preventing life-altering complications.

Managing Hyperinsulinism: Goals and Treatment Approaches

The primary goal when treating hyperinsulinism is maintaining normal blood glucose levels—specifically keeping blood sugar above 60 mg/dL—to protect the brain from damage caused by inadequate fuel supply. Unlike other causes of low blood sugar, hyperinsulinism is particularly dangerous because insulin (a hormone produced by the pancreas that regulates blood sugar) simultaneously blocks the body’s ability to produce alternative energy sources like ketones that the brain normally uses when glucose runs low.^[1] This dual effect creates a heightened risk of serious neurological injury if the condition is not promptly recognized and aggressively treated.

Treatment strategies depend heavily on whether the hyperinsulinism is temporary or persistent, whether it affects the entire pancreas (diffuse form) or just a small area (focal form), and how the patient responds to initial medications. Infants with hyperinsulinism may need extremely high glucose infusion rates—sometimes 20 to 30 milligrams per kilogram per minute—far exceeding what healthy babies require.^[6] The condition can range from mild cases that resolve on their own within weeks to severe forms requiring lifelong management or surgical intervention.

Medical societies recognize that managing hyperinsulinism requires a multidisciplinary approach involving pediatric endocrinologists, neonatologists, surgeons, geneticists, and specialized nursing staff. International guidelines emphasize the importance of diagnosing the condition quickly and instituting immediate treatment to reduce the number of children who suffer brain injury from repeated episodes of hypoglycemia.^[10] The treatment plan must be individualized based on the underlying genetic cause, the severity of hypoglycemia, and the patient’s response to therapy.

Standard Medical Treatment for Hyperinsulinism

The cornerstone of medical therapy for hyperinsulinism is diazoxide, which is currently the only medication approved by the United States Food and Drug Administration specifically for treating this condition.^[11] Diazoxide works by opening special channels in the insulin-producing cells of the pancreas called KATP channels, which helps reduce insulin secretion. The World Health Organization considers diazoxide an essential medicine, though unfortunately it remains unavailable in many countries around the world.

Diazoxide is typically given at doses averaging 12.5 milligrams per kilogram per day, though the range can vary from as low as 2 to as high as 60 milligrams per kilogram daily depending on individual patient needs.^[12] Clinical experience shows that diazoxide works effectively in approximately 84 percent of patients treated for hyperinsulinism. For those who respond well to the medication, treatment duration until the condition resolves averages around 57 months, though some children may need therapy for shorter or longer periods.

Common side effects of diazoxide include fluid retention, increased body hair growth, and gastrointestinal symptoms like nausea or loss of appetite. Most of these effects are not severe and can be managed with supportive care. A medication called hydrochlorothiazide, which is a diuretic that helps remove excess fluid from the body, is often given alongside diazoxide to reduce swelling. While rare serious side effects such as heart problems have been reported in about 3.7 percent of cases, experts note that proving a direct causal relationship between diazoxide and severe complications remains uncertain.^[12]

When diazoxide proves ineffective or cannot be used, somatostatin analogues become the next treatment option. The most commonly used medications in this class are octreotide and lanreotide. These synthetic hormones work by mimicking somatostatin, a naturally occurring substance that inhibits insulin secretion. Octreotide is usually administered through continuous infusion under the skin or by multiple daily injections, with average doses around 14.9 micrograms per kilogram per day (ranging from 2.3 to 50 micrograms per kilogram per day).^[12] Lanreotide, which has a longer-acting formulation, can be given as a monthly injection at doses averaging 67.3 milligrams per month.

Somatostatin analogues are used in approximately 16 percent of patients with hyperinsulinism, with an average treatment duration of 49 months until remission occurs. The most frequently encountered side effect is tachyphylaxis, a phenomenon where the medication becomes less effective over time as the body adapts to it. Mild gastrointestinal symptoms such as abdominal discomfort, bloating, or loose stools are also common but usually manageable. There has been concern about whether long-term use might affect growth, but studies indicate the risk of persistent growth deceleration is actually quite low, occurring in fewer than 5 percent of treated children.^[12]

Other medications used less frequently include nifedipine, a calcium channel blocker that affects calcium flow into insulin-producing cells, thereby reducing insulin release. This medication is used in roughly 4 percent of hyperinsulinism cases.^[12] Glucagon, a hormone that raises blood sugar by stimulating glucose release from the liver, can be administered by continuous infusion in severe cases, though only about 1 percent of patients require this approach. Glucagon is particularly useful as a short-term measure to stabilize blood glucose levels while other treatment decisions are being made.

International guidelines recommend that before discharging any infant from the hospital, doctors should perform a supervised fasting study lasting 6 to 8 hours to ensure the child can safely tolerate a missed or inadequate feeding at home without experiencing dangerous drops in blood sugar.^[6] Families must also receive thorough training on recognizing symptoms of low blood sugar and managing emergency situations, including how to operate infusion pumps if continuous medication delivery is required.

Surgical Treatment Options

When medications fail to control blood glucose levels adequately, surgical removal of pancreatic tissue becomes necessary. The type and extent of surgery depends on whether the hyperinsulinism is focal or diffuse. For focal hyperinsulinism, where only a small, isolated area of the pancreas is abnormal, surgical removal of just that lesion can be curative. A specialized imaging test called 18F-DOPA PET scan (positron emission tomography using fluorine-18-labeled dihydroxyphenylalanine) helps surgeons identify the exact location of the focal lesion within the pancreas.^[7]

When focal disease is confirmed and successfully removed, children are often cured completely and no longer need any medications. This represents the best possible outcome for patients with hyperinsulinism. Surgical techniques have evolved to include minimally invasive laparoscopic approaches when feasible, which involve smaller incisions and typically result in faster recovery times compared to traditional open surgery.

For diffuse hyperinsulinism, where insulin-producing cells throughout the entire pancreas are affected, the surgical approach is more complex. Patients with severe, medication-resistant diffuse disease typically require a near-total pancreatectomy, meaning removal of approximately 95 to 98 percent of the pancreas.^[7] This extensive surgery carries significant consequences. While it often controls the hyperinsulinism, many patients subsequently develop insulin-dependent diabetes because so little insulin-producing tissue remains. The balance surgeons must strike is removing enough pancreatic tissue to eliminate dangerous hypoglycemia while preserving sufficient function to avoid—or at least minimize the severity of—resulting diabetes.

The historical first successful pancreatectomy for hyperinsulinism was performed in 1934 by surgeon Evarts Graham in St. Louis, remarkably occurring two decades before the condition was even formally described in medical literature.^[2] Modern surgical outcomes have improved substantially due to better understanding of the disease, advanced imaging techniques that help distinguish focal from diffuse forms, and refined surgical methods including both laparoscopic and open procedures performed at specialized centers.

Deciding whether to proceed with surgery requires careful consideration. The risk of ongoing neurological damage from recurrent severe hypoglycemia must be weighed against surgical risks and the likelihood of developing diabetes. International consensus guidelines emphasize that while attempts should be made to control blood glucose levels medically before considering surgery, pancreatectomy should not be delayed in patients with severe, uncontrolled hypoglycemia because irreversible brain damage can occur rapidly.^[6]

Emerging Treatments in Clinical Research

While diazoxide has been the mainstay of medical treatment since the 1960s, researchers have been working to identify new therapeutic options for patients who do not respond to currently available medications. One of the most promising developments involves the drug sirolimus, also known by its brand name rapamycin. Sirolimus was originally developed as an immunosuppressant medication to prevent organ rejection in transplant patients, but researchers discovered it may help control insulin secretion in certain forms of hyperinsulinism.^[7]

Sirolimus works through a different mechanism than existing hyperinsulinism medications. It acts on a cellular pathway called mTOR (mechanistic target of rapamycin), which plays a role in regulating cell growth and metabolism. By inhibiting this pathway, sirolimus appears to reduce the excessive insulin secretion that characterizes hyperinsulinism. Clinical trials evaluating sirolimus have shown encouraging preliminary results in some patients with diazoxide-unresponsive disease, though the medication is not yet formally approved for this indication.^[6]

Research into new treatments is ongoing at specialized centers around the world. These trials typically progress through three phases. Phase I trials focus primarily on safety, determining what doses humans can tolerate and identifying potential side effects. Phase II trials examine whether the treatment actually works—in this case, whether it effectively controls blood glucose levels and reduces episodes of hypoglycemia. Phase III trials compare the new treatment directly against current standard therapies to determine if it offers advantages in effectiveness or safety.

The development of continuous glucose monitoring systems has also transformed both clinical care and research in hyperinsulinism. These devices, which measure blood sugar levels continuously throughout the day and night using a small sensor placed under the skin, provide much more detailed information about glucose patterns than traditional finger-stick testing. The availability of this technology has made it easier to monitor patients’ responses to treatments and detect problematic glucose drops that might otherwise go unnoticed.^[1] Continuous glucose monitoring has become an important tool both for managing patients on a day-to-day basis and for evaluating new therapies in clinical trials.

Advances in understanding the genetic basis of hyperinsulinism have opened additional avenues for potential future therapies. Scientists have identified mutations in twelve different genes that can cause the condition, including ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1, UCP2, HNF4A, HNF1A, HK1, PGM1, and PMM2.^[7] Each of these genes plays a specific role in regulating insulin secretion from the pancreatic beta cells. Understanding exactly how different genetic defects lead to excessive insulin production may eventually allow researchers to develop targeted therapies designed to correct specific molecular abnormalities.

Gene therapy approaches, while still in very early research stages, represent another potential future direction. These experimental techniques aim to correct genetic defects at their source, potentially offering curative treatment for forms of hyperinsulinism caused by specific gene mutations. However, substantial additional research is needed before such approaches could become available for clinical use.

Clinical trials for hyperinsulinism are conducted at specialized centers primarily in North America, Europe, and increasingly in other regions as expertise spreads globally. Patient eligibility typically depends on factors such as age, specific genetic diagnosis, severity of disease, and whether the patient has responded to standard medications. The international hyperinsulinism community maintains registries and collaborative networks to facilitate research and ensure families can access the most current treatment information.^[11]

Most common treatment methods

• Diazoxide therapy
  • Oral medication given at 12.5 mg/kg/day on average (range 2-60 mg/kg/day)
  • Opens KATP channels in pancreatic beta cells to reduce insulin secretion
  • Effective in approximately 84% of patients with hyperinsulinism
  • Average treatment duration of 57 months until remission
  • Common side effects include fluid retention and increased hair growth
  • Only FDA-approved medication specifically for hyperinsulinism
• Somatostatin analogue therapy
  • Octreotide given at average dose of 14.9 micrograms/kg/day through injection or continuous infusion
  • Lanreotide administered as monthly injection at average 67.3 mg/month
  • Used in approximately 16% of patients, particularly those unresponsive to diazoxide
  • Average treatment duration of 49 months until remission
  • Common side effects include tachyphylaxis and mild gastrointestinal symptoms
  • Risk of persistent growth deceleration is low (less than 5%)
• Surgical intervention
  • Focal lesion removal can cure patients with localized disease
  • 18F-DOPA PET scan helps identify exact location of focal lesions
  • Near-total pancreatectomy (95-98% removal) for severe diffuse disease
  • Laparoscopic techniques available for minimally invasive surgery when feasible
  • Risk of developing insulin-dependent diabetes after extensive pancreas removal
• Supportive glucose management
  • High-concentration dextrose infusions (up to 20-25% concentration)
  • Glucose infusion rates may reach 15-30 mg/kg/min in severe cases
  • Frequent feeding schedules to prevent blood sugar drops
  • Continuous glucose monitoring systems for real-time tracking
• Additional medications
  • Nifedipine (calcium channel blocker) used in about 4% of cases
  • Glucagon continuous infusion for severe cases requiring stabilization
  • Hydrochlorothiazide given with diazoxide to reduce fluid retention
  • Sirolimus being studied as emerging treatment option for diazoxide-unresponsive patients

Living with Hyperinsulinism: Long-Term Outlook and Monitoring

Many children with hyperinsulinism can achieve clinical remission, meaning their condition improves to the point where medications can eventually be stopped. For transient forms of hyperinsulinism—those caused by temporary stressors such as problems during delivery or maternal diabetes—resolution often occurs within weeks to months. Even some persistent genetic forms may become easier to manage as children grow older, with some patients able to discontinue medications after several years of treatment.

Long-term neurological outcomes depend heavily on how quickly the diagnosis was made and how effectively blood glucose levels were maintained during the critical early period. Children who experienced frequent or prolonged episodes of severe hypoglycemia before diagnosis are at higher risk for developmental delays, learning disabilities, cerebral palsy, or seizure disorders.^[7] However, when hyperinsulinism is diagnosed promptly and blood glucose is kept consistently above 60 mg/dL, most children develop normally with a full range of cognitive, emotional, and social skills.

Patients require ongoing monitoring even after treatment is established. This includes regular blood glucose checks—traditionally through finger-stick testing before meals and when symptoms occur, though increasingly supplemented or replaced by continuous glucose monitoring. Regular follow-up appointments assess growth, development, and any side effects from medications. For patients who have undergone pancreatectomy, monitoring must also watch for signs of diabetes developing over time.

Families play a crucial role in managing hyperinsulinism at home. Parents and caregivers must learn to recognize early warning signs of low blood sugar, such as excessive hunger, irritability, shakiness, or unusual sleepiness. In infants, symptoms can be particularly subtle—perhaps only poor feeding or lethargy—making vigilance essential. Older children may be able to communicate feelings of weakness, confusion, or hunger that signal dropping glucose levels.

Adequate training in emergency management is vital. This includes knowing how to administer fast-acting carbohydrates or glucose gel by mouth when the child is conscious and alert, when to check blood sugar levels, and when to seek emergency medical care. Some families keep emergency glucagon kits at home for severe episodes where the child cannot safely swallow, though this requires proper instruction on how to prepare and administer the injection.

The psychosocial impact of managing a rare, chronic condition should not be underestimated. Families often benefit from connecting with support organizations and other families dealing with hyperinsulinism. These connections provide emotional support, practical advice, and a sense of community that can be invaluable when navigating the challenges of this complex disorder. Several patient advocacy organizations maintain online resources, support networks, and educational materials specifically for hyperinsulinism families.^[11]

Research continues to improve outcomes for hyperinsulinism patients. Better diagnostic tools, including rapid genetic testing and advanced imaging, allow earlier and more accurate identification of disease type. New therapeutic options are being developed and tested. The establishment of specialized treatment centers with multidisciplinary teams experienced in managing hyperinsulinism has substantially improved care quality and patient outcomes. While hyperinsulinism remains a serious condition requiring intensive management, the prognosis for affected children has improved dramatically over recent decades, and ongoing research offers hope for even better treatments in the future.